New antithrombotic drugs: American College of Chest physicians evidence-based clinical practice guidelines (8th edition)

Chest

Volumn 133, Issue 6 SUPPL. 6, 2008, Pages 234S-256S

  Weitz, Jeffrey I ^a,c   Hirsh, Jack ^a   Samama, Meyer M ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b HÔTEL DIEU   (France)

^c NONE   (Canada)

Author keywords

Anticoagulants; Antiplatelet drugs; Antithrombotic drug; Fibrinolytic agents

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBIN; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; AVIDIN; AZD 0837; BB 10153; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 9A; CANGRELOR; CLOPIDOGREL; CYCLOOXYGENASE 1; DABIGATRAN; DU 176B; E 5555; FIBRINOLYTIC AGENT; FLOVAGATRAN; FONDAPARINUX; H 33857; H 41504; LOW MOLECULAR WEIGHT HEPARIN; N [2 [4 (1 METHYL 4 PIPERIDINYL) 1 PIPERAZINYL] 2 OXO 1 PHENYLETHYL] 1H INDOLE 6 CARBOXAMIDE; NEW DRUG; PROTEIN C; PROTEINASE ACTIVATED RECEPTOR 1; PRT 054021; PURINERGIC P2Y12 RECEPTOR; RB 006; RB 007; RECOMBINANT THROMBOMODULIN; SCH 530348; SR 123781A; SSR 12517E; TERUTROBAN; THIENOPYRIDINE DERIVATIVE; THROMBIN; THROMBIN INHIBITOR; THROMBOXANE A2; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; TICAGRELOR; TICLOPIDINE; TTP 889; UNINDEXED DRUG; WARFARIN; YM 150;

ANTICOAGULANT THERAPY; BLEEDING; BRADYCARDIA; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG EFFECT; DRUG INDICATION; DRUG MECHANISM; DYSPNEA; EVIDENCE BASED PRACTICE; HUMAN; LIVER TOXICITY; MEDICAL SOCIETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE;

CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DRUGS, INVESTIGATIONAL; EVIDENCE-BASED MEDICINE; FIBRINOLYTIC AGENTS; HUMANS; THROMBOLYTIC THERAPY;

EID: 45949083155     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.08-0673     Document Type: Article

References (147)

1. Freiman DG. The structure of thrombi. In: Colman RW, Hirsh J, Marder X, et al, eds. Hemostasis and thrombosis: basic principles and clinical practice. 2nd ed. Philadelphia, PA: JB Lippincott, 1987; 1123-1135
2. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324:71-86
3. Tran H, Anand SS. Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease. JAMA 2004; 292:1867-1874
4. Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet 2006; 367:606-617
5. Macchi L, Sorel N, Christiaens L. Aspirin resistance: definitions, mechanisms, prevalence and clinical significance. Curr Pharm Des 2006; 12:251-258
6. Hovens MM, Snoep JD, Eikelboom JC, et al. Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. Am Heart J 2007; 153:175-181
7. Savi P, Herbert JM. Clopidogrel and ticlopidine: p2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost 2005; 31:174-183
8. Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107:2908-2913
9. Gurbel PA, Lau WC, Bliden KP, et al. Clopidogrel resistance: implications for coronary stenting. Curr Pharm Des 2006; 12:1261-1269
10. Geisler T, Gawaz M. Variable response to clopidogrel in patients with coronary artery disease. Semin Thromb Hemost 2007; 33:196-202
11. von Beckerath N, Taubert D, Pogatsa-Murray G, et al. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen; choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation 2005; 112:2946-2950
12. Peters RJ, Mehta SR, Fox KA, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 2003; 108:1682-1687
13. Fox KA, Mehta SR, Peters R, et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation 2004; 110:1202-1208
14. Kapetanakis EI, Medlam DA, Boyce SW, et al. Clopidogrel administration prior to coronary artery bypass grafting surgery: the cardiologist's panacea or the surgeon's headache? Eur Heart J 2005; 26:576-583
15. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345:494-502
16. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354:1706-1717
17. Turpie AG, Bauer KA, Eriksson BI, et al. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002; 162:1833-1840
18. Turpie AG, Bauer KA, Eriksson BI, et al. Superiority of fondaparinux over enoxaparin in preventing venous thromboembolism in major orthopedic surgery using different efficacy end points. Chest 2004; 126:501-508
19. Agnelli G, Bergqvist D, Cohen AT, et al. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg 2005; 92:1212-1220
20. Buller HR, Davidson BL, Decousus H, et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004; 140:867-873
21. Buller HR, Davidson BL, Decousus H, et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003; 349:1695-1702
22. Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006; 354:1461-1476
23. Weitz JI. Emerging anticoagulants for the treatment of venous thromboembolism. Thromb Haemost 2006; 96:274-284
24. Herbert JM, Herault JP, Bernat A, et al. SR123781A, a synthetic heparin mimetic. Thromb Haemost 2001; 85:852-860
25. Lee WM, Larrey D, Olsson R, et al. Hepatic findings in long-term clinical trials of ximelagatran. Drug Saf 2005; 28:351-370
26. Boudes PF. The challenges of new drugs benefits and risks analysis: lessons from the ximelagatran FDA Cardiovascular Advisory Committee. Contemp Clin Trials 2006; 27:432-440
27. Gaussem P, Reny JL, Thalamas C, et al. The specific thromboxane receptor antagonist S18886: pharmacokinetic and pharmacodynamic studies. J Thromb Haemost 2005; 3:1437-1445
28. 2 receptor antagonist S18886 in patients with coronary artery disease treated with aspirin. J Am Coll Cardiol 2003; 41:1198-1204
29. Tantry US, Bliden KP, Gurbel PA. Prasugrel. Expert Opin Investig Drugs 2006; 15:1627-1633
30. Lau WC, Gurbel PA, Watkins PB, et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 2004; 109:166-171
31. Neubauer H, Mugge A. Thienopyridines and statins: assessing a potential drug-drug interaction. Curr Pharm Res 2006; 12:1271-1280
32. Brandt JT, Close SL, Iturria SJ, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 2007; 5:2429-2436
33. Jakubowski JA, Matsushima N, Asai F, et al. A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y(12) inhibitor, compared with clopidogrel in healthy humans. Br J Clin Pharmacol 2007; 63:421-430
34. Wiviott SD, Antman EM, Winters KJ, et al. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 Trial. Circulation 2005; 111:3366-3373
35. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357:2001-2015
36. van Giezen JJ, Humphries RG. Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Semin Thromb Hemost 2005; 31:195-204
37. Fugate SE, Cudd LA. Cangrelor for treatment of coronary thrombosis. Ann Pharmacother 2006; 40:925-930
38. Greenbaum AB, Grines CL, Bittl JA, et al. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. Am Heart J 2006; 151:689.e1-689.e10
39. Tantry US, Bliden KP, Gurbel PA. AZD6140. Expert Opin Investig Drugs 2007; 16:225-229
40. Husted S, Emanuelsson H, Heptinstall S, et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6f40 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006; 27:1038-1047
41. Serebruany VL, Stebbing J, Atar D. Dyspnoea after antiplatelet agents: the AZD6140 controversy. Int J Clin Pract 2007; 6L529-533
42. Seiler SM, Bernatowicz MS. Peptide-derived protease-activated receptor-1 (PAR-1) antagonists. Curr Med Chem 2003; 1:1-11
43. Chackalamannil S, Ahn H-S, Xia Y, et al. Potent non-peptide thrombin receptor antagonists. Curr Med Chem 2003; 1:37-45
44. Abraham E, Reinhart K, Svoboda P, et al. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med 2001; 29:2081-2089
45. Abraham E, Reinhart K, Opal S, et al. Efficacy and safety of tifaeogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003; 290:238-247
46. Cappello M, Vlasuk GP, Bergum PW, et al. Ancylostoma caninum anticoagulant peptide: a hookworm-derived inhibitor of human coagulation factor Xa. Proc Natl Acad Sci USA 1995; 92:6152-6156
47. Bergum PW, Cruikshank A, Maki S, et al. Role of zymogen and activated factor X as scaffolds for the inhibition of the blood coagulation factor VIIa-tissue factor complex bv recombinant nematode anticoagulant protein c2. J Biol Chem 2001; 276:10063-10071
48. Vlasuk GP, Bradbury A, Lopez-Kinniger L, et al. Pharmacokinetics and anticoagulant properties of the factor VIIa-tissue factor inhibitor recombinant Nematode Anticoagulant Protein c2 following subcutaneous administration in man: dependence on the stoichiometric binding to circulating factor X. Thromb Haemost 2003; 90:803-812
49. Lee A, Agnelli G, Buller H, et al. Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation 2001; 104:74-78
50. Giugliano RP, Wiviott SD, Morrow DA, et al. Addition of a tissue-factor/factor VIIa inhibitor to standard treatments in NSTE-ACS managed with an early invasive strategy: results of the Phase II ANTHEM-TIMI 32 double-blind randomized clinical trial [abstract]. Program and Abstracts of the American Heart Association Meeting, Dallas, TX, November, 2005:2095/C16
51. Moons AH, Peters RJ, Bijsterveld NR, et al. Recombinant nematode anticoagulant protein e2, an inhibitor of the tissue factor/factor VIIa complex, in patients undergoing elective coronary angioplasty. J Am Coll Cardiol 2003; 41:2147-2153
52. Taylor FB Jr. Role of tissue factor and factor VIIa in the coagulant and inflammatory response to LD100 Escherichia coli in the baboon. Haemostasis f996; 26:83-91
53. Jang Y, Guzman LA, Lineoff AM, et al. Influence of blockade at specific levels of the coagulant cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. Circulation 1995; 92:3041-3050
54. Lineoff AM. First clinical investigation of a tissue-factor inhibitor administered during percutaneous coronary revascularization: a randomized, double-blind, dose-escalation trial assessing safety and efficacy of FFR-FVIIa in percutaneous transluminal coronary angioplasty (ASIS) trial [abstract]. J Am Coll Cardiol 2000; 36:312
55. Rusconi CP, Scardino E, Lavzer J, et al. RNA aptamers as reversible antagonists of coagulation factor IXa. Nature 2002; 419:90-94
56. Dyke CK, Steinhubl SR, Kleiman NS, et al. First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity. Circulation 2006; 114:2490-2497
57. Nimjee SM, Keys JR, Pitoc GA, et al. A novel antidotecontrolled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery. Mol Ther 2006; 14:408-415
58. Eriksson BI, Quinlan DJ. Oral anticoagulants in development: focus on thromboprophylaxis in patients undergoing orthopedic surgery. Drugs 2006; 66:1411-1429
59. Rezaie AR. Prothrombin protects factor Xa in the prothrombinase complex from inhibition by the heparin-antithrombin complex. Blood 2001; 97:2308-2313
60. Brufatto N, Nesheim ME. The use of prothrombin (S525C) labeled with fluorescein to directly study the inhibition of prothrombinase by antithrombin during prothrombin activation. J Biol Chem 2001; 276:17663-17671
61. Krishnaswamy S, Vlasuk GP, Bergum PW. Assembly of the prothrombinase complex enhances the inhibition of bovine factor Xa by tick anticoagulant peptide. Biochemistry 1994; 33:7897-7907
62. Herault JP, Bernat A, Pflieger AM, et al. Comparative effects of two direct and indirect factor Xa inhibitors on free and clot-bound prothrombinase. J Pharmacol Exp Ther 1997; 283: 16-22
63. Boneu B, Necciari J, Cariou R, et al. Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/ORG31540) with high affinity to antithrombin III in man. Thromb Haemost 1995; 74:1468-1473
64. Cohen AT, Davidson BL, Callus AS, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 2006; 332:325-329
65. Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 2006; 295:1519-1530
66. Herbert JM, Herault JP, Bernat A, et al. Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. Blood 1998; 91:4197-4205
67. Persist Investigators. A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis: a phase II evaluation. J Thromb Haemost 2004; 2:47-53
68. Buller HR, Cohen AT, Davidson B, et al. Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med 2007; 357:1094-1104
69. Buller HR, Cohen AT, Davidson B, et al. Extended prophylaxis of venous thromboembolism with idraparinux. N Engl J Med 2007; 357:1105-1112
70. Herbert JM, Herault JP, Bernat A, et al. SR123781A, a synthetic heparin mimetic. Thromb Haemost 2001; 85:852-860
71. Becker DL, Fredenburgh JC, Stafford AR, et al. Exosites 1 and 2 are essential for protection of fibrin-bound thrombin from heparin-catalyzed inhibition by antithrombin and heparin cofactor II. J Biol Chem 1999; 274:6226-6233
72. Herault JP, Cappelle M, Bernat A, et al. Effect of SanOrg123781A, a synthetic hexadecasaceharide, on clotbound thrombin and factor Xa in vitro and in vivo. J Thromb Haemost 2003; 1:1959-1965
73. Herbert JM, Bernat A, Dol F, et al. DX-9065a, a novel synthetic, selective and orally active inhibitor of Factor Xa: in vitro and in vivo studies. J Pharmacol Exp Ther 1996; 276:1030-1038
74. Maruyama I, Tanaka M, Kunitada S, et al. Tolerability, pharmacokinetics and pharmacodynamics of DX-9065a, a new synthetic potent anticoagulant and specific Factor Xa inhibitor, in healthy male volunteers. Clin Pharmacol Ther 1996; 66:258-264
75. Becker RC, Alexander JH, Dyke C, et al. Effect of the novel direct Factor Xa inhibitor DX-9065a on thrombin generation and inhibition among patients with stable atherosclerotic coronaiy artery disease. Thromb Res 2006; 117:439-446
76. Alexander JH, Yang H, Becker RC, et al. First experience with direct, selective Factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS Trial. J Thromb Haemost 2005; 3:436-438
77. Alexander JH, Dyke CK, Yang H, et al. Initial experience with factor Xa inhibition in percutaneous coronary intervention: the XaNADU-PCI pilot. J Thromb Haemost 2004; 2:234-241
78. Paecaly A, Ozooux ML, Chu V, et al. Pharmcodynamic markers in the early clinical assessment of otamixaban, a direct Factor Xa inhibitor. Thromb Haemost 2005; 94:1156-1163
79. Hinder M, Friek A, Jordaan P, et al. Direct and rapid inhibition of factor Xa by otamixaban: a pharmacokinetic and pharmacodynamic investigation in patients with coronary artery disease. Clin Pharmacol Ther 2006; 80:691-702
80. Cohen M, Bhatt DL, Alexander JH, et al. Randomized, double-blind, dose-ranging study of otamixaban, a novel, paternal, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial. Circulation 2007; 115:2642-2651
81. Lassen MR, Davidson BL, Gallus A, et al. A Phase II randomized, double blind, five-arm, parallel group, doseresponse study of a new oral directly acting Factor Xa inhibitor, razaxaban, for the prevention of deep vein thrombosis in knee replacement surgery [abstract 41]. Blood 2003; 102:15a
82. Kan H, Bing H, Grace JE, et al. Preclinical pharmacokinetic and metabolism of apixaban, a potent and selective factor Xa inhibitor [abstract]. Blood 2006; 108;910
83. Lassen MR, Davidson BL, Gallus A, et al. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thronib Haemost 2007; 5:2368-2375
84. Kubitza D, Becka M, Wensing G, et al. Safety, pharmacodynamics of BAY 59-7939, an oral, direct Factor Xa inhibitor, after multiple dosing in healthy male subjects. Eur J Clin Pharmcol 2005; 61:873-880
85. Eriksson BI, Borris LC, Dahl OE, et al. Dose-escalation study of rivaroxaban (BAY 59-7939), an oral, direct Factor Xa inhibitor, for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Res 2007; 120:685-693
86. Eriksson BI, Borris L, Dahl OE, et al. Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2006; 4:121-128
87. Turpie AG, Fisher WD, Bauer KA, et al. BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement; a phase II dose-ranging study. J Thromb Haemost 2005; 3:2479-2486
88. Fisher WD, Eriksson BI, Bauer KA, et al. Rivaroxaban for thromboprophylaxis after orthopedic surgery: pooled analysis of two studies. Thromb Haemost 2007; 97:931-937
89. Eriksson BI, Borris LC, Dahl OE, et al. A once daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation 2006; 114:2374-2381
90. Lassen MR, Turpie AG, Roseneher N, et al. Late breaking clinical trial: rivaroxaban, an oral, direct factor Xa inhibitor, for the prevention of venous thromboembolism in total knee replacement surgery: results of the RECORD-3 study-late breaking [abstract]. J Thromb Haemost 2007; 5(suppl 2):OS-006B
91. Agnelli G, Gallus A, Goldhaber SZ, et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients with Acute Symptomatic Deep-Vein Thrombosis) study. Circulation 2007; 116:180-187
92. Buller HR, EINSTEIN-DVT Study Group. Once-daily treatment with an oral, direct factor Xa inhibitor, rivaroxaban (BAY 59-7939), in patients with acute, symptomatic deep vein thrombosis: the EINSTEIN-DVT dose-finding study [abstract P4568]. Eur Heart J 2006; 27(suppl):761
93. Agnelli G, Haas S, Ginsberg JS, et al. A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement. J Thromb Haemost 2007; 5:746-753
94. Eriksson BI, Turpie AG, Lassen MR, et al. A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery. J Thromb Haemost 2007; 5:1660-1665
95. Turpie AG. Oral direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler Thromb Vasc Biol 2007; 27:1238-1247
96. Turpie AG, Gent M, Bauer K, et al. Evaluation of the factor Xa (FXa) inhibitor, PRT054021 (PRT021), against enoxaparin in a randomized trial for the prevention of venous thromboembolic events after total knee replacement (EXPERT) [abstract]. J Thromb Haemost 2007; 5(suppl 2):P-T-652
97. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709
98. Abraham E, Laterre PF, Garg R, et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005; 353:1332-1341
99. Parkinson JF, Grinnell BW, Moore RE, et al. Stable expression of a secretable deletion mutation of recombinant human thrombomodulin in mammalian cells. J Biol Chem 1990; 265:12602-12610
100. Kearon C, Comp P, Doukeris JD, et al. Dose-response study of recombinant human soluble thrombomodulin (ART-123) in the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2005; 3:962-968
101. Weitz JI, Buller HR. Direct thrombin inhibitors in acut coronary syndromes: present and future. Circulation 2002; 105:1004-1011
102. Weitz JI, Crowther M. Direct thrombin inhibitors. Thromb Res 2002; 106:V275-V284
103. Avgerinos GC, Turner BG, Gorelick KJ, et al. Production and clinical development of a Hansenula polymorphaderived PEGylated hirudin. Semin Thromb Hemost 2001; 27:357-372
104. Tommey JR, Abboud MA, Valocik RE, et al. A comparison of the β-D-xyloside, odiparcil, to warfarin in a rat model of venous thrombosis. J Thromb Haemost 2006; 4:1989-1996
105. Bates SM, Buller H, Lassen MR, et al. A phase II double-blind placebo-controlled parallel-group randomized study of extended prophylaxis with odiparcil following total hip arthroplasty (THA) [abstract]. J Thromb Haemost 2007; 5(suppl 2):P-M-653
106. Gustafsson D, Nystrom J, Carlsson S, et al. The direct thrombin inhibitor melagatran and its oral prodrug H376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res 2001; 101:171-181
107. Testa L, Andreotti F, Biondi Zoccai GG, et al. Ximelagatran/melagatran against conventional anticoagulation; a meta-analysis based on 22,639 patients. Int J Cardiol 2007; 122:117-124
108. Lee WM, Larrey D, Olsson R, et al. Hepatic findings in long-term clinical trials of ximelagatran. Drug Saf 2005; 28:351-370
109. Gustafsson D. Oral direct thrombin inhibitors in clinical development. J Int Med 2003; 254:322-334
110. Weitz JI. Emerging anticoagulants for the treatment of venous thromboembolism. Thromb Haemost 2006; 96:274-284
111. Stangier J, Rathgen K, Stahle H, et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007; 64:292-303
112. Eriksson BI, Dahl OE, Buller HR, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 2005; 3:103-111
113. Eriksson BI, Dahl OE, Roseneher N, et al. Oral dabigatran etexilate versus subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007; 5:2178-2185
114. Eriksson BI, Dahl OE, Roseneher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomized, double-blind, non-inferiority trial. Lancet 2007; 370:949-956
115. Caprini JA, Hwang E, Hantel S, et al. The oral direct thrombin inhibitor, dabigatran etexilate, is effective and safe for prevention of major venous thromboembolism following major orthopedic surgery [abstract]. J Thromb Haemost 2007; 5(suppl 2):O-W-050
116. Wallentin L, Ezekowitz M, Simmers TA, et al. Safety and efficacy of a new oral direct thrombin inhibitor dabigatran in atrial fibrillation: a dose finding trial with comparison to warfarin [abstract]. Eur Heart J 2005; 26:482
117. Fujii S, Sawa H, Sobel BE. Inhibition of endothelial cell expression of plasminogen activator inhibitor type-1 by gemfibrozil. Thromb Haemost 1993; 70:642-647
118. Brown SL, Sobel BE, Fujii S. Attenuation of the synthesis of plasminogen activator inhibitor type 1 by niacin: a potential link between lipid lowering and fibrinolysis. Circulation 1995; 92:767-772
119. Kvassman J, Lawrence D, Shore J. The acid stabilization of plasminogen activator inhibitor-1 depends on protonation of a single group that affects loop insertion into beta-sheet A. J Biol Chem 1995; 270:27942-27947
120. Eitzman DT, Fay WP, Lawrence DA, et al. Peptide-mediated inactivation of recombinant and platelet plasminogen activator inhibitor-1 in vitro. J Clin Invest 1995; 95:2416-2420
121. Friederich P, Levi M, Biemond B, et al. Low-molecular-weight inhibitor of PAI-1 (XR5118) promotes endogenous fibrinolysis and reduces postthrombolysis thrombus growth in rabbits. Circulation 1997; 96:916-921
122. Sakharov DV, Plow EF, Rijken DC. On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B. J Biol Chem 1997; 272:14477-14482
123. Redlitz A, Nicolini FA, Malycky JL, et al. Inducible carboxypeptidase activity: a role in clot lysis in vivo. Circulation 1996; 93:1328-1330
124. Klement P, Liao P, Bajzar L. A novel approach to arterial thrombolysis. Blood 1999; 94:2735-2743
125. Nagashima M, Werner M, Wang M, et al. An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model. Thromb Res 2000; 98:333-342
126. Guimaraes AH, Barrett-Bergshoeff MM, Criscuoli M, et al. Fibrinolytic efficacy of Amediplase, Tenecteplase and scu-PA in different external plasma clot lysis models: sensitivity to the inhibitory action of thrombin activatable fibrinolysis inhibitor (TAFI). Thromb Haemost 2006; 96:325-330
127. Islam I, Bryant J, May K, et al. 3-Mercaptopropionic acids as efficacious inhibitors of activated thrombin aetivatable fibrinolysis inhibitor (TAFIa). Bioorg Med Chem Lett 2007; 17:1349-1354
128. Schneider M, Nesheim M. Reversible inhibitors of TAFIa can both promote and inhibit fibrinolysis. J Thromb Haemost 2003; 1:147-154
129. Walker J, Hughes B, James I, et al. Stabilization versus inhibition of TAFIa by competitive inhibitors in vitro. J Biol Chem 2003; 278:8913-8921
130. Mosesson MW. The roles of fibrinogen and fibrin in hemostasis and thrombosis. Semin Hematol 1992; 29:177-178
131. Muszbek L, Adany R, Mikkola H. Novel aspects of blood coagulation factor XIII: I. Structure, distribution, activation, and function. Crit Rev Clin Lab Sci 1996; 33:357-421
132. Seale L, Finney S, Sawyer RT, et al. Tridegin, a novel peptidic inhibitor of factor XIIIa from the leech, Haementeria ghilianii, enhances fibrinolysis in vitro. Thromb Haemost 1997; 77:959-963
133. Finney S, Seale L, Sawyer RT, et al. Tridegin, a new peptidic inhibitor of factor XIIIa, from the blood-sucking leech Haementeria ghilianii. Biochem J 1997; 324:797-805
134. Baskova IP, Nikonov GI. Destabilase, the novel epsilon-(gamma-Glu)-Lys isopeptidase with thrombolytic activity. Blood Coagul Fibrinolysis 1991; 2:167-172
135. Zavalova L, Lukyanov S, Baskova I, et al. Genes from the medicinal leech (Hirudo medicinalis) coding for unusual enzymes that specifically cleave endo-epsilon (gamma-Glu)-Lys isopeptide bonds and help to dissolve blood clots. Mol Geu Genet 1996; 253:20-25
136. Noble S, McTavish D. Reteplase: a review of its pharmacological properties and clinical efficacy in the management of acute myocardial infarction. Drugs 1996; 52:589-605
137. Dunn CJ, Goa KL. Tenetecplase: a review of its pharmacology and therapeutic efficacy in patients with acute myocardial infarction. Am J Cardiovasc Drugs 2001; 1:51-66
138. Llevadot J, Giugliano RP, Antman EM. Bolus fibrinolytic therapy in acute myocardial infarction. JAMA 2001; 286:442-449
139. Deitcher SR, Funk WD, Buchanan J, et al. Alfimeprase: a novel recombinant direct-acting fibrinolytic. Expert Opin Biol Ther 2006; 6:1361-1369
140. Toombs CF. Alfimeprase: pharmacology of a novel fibrinolytic metalloproteinase for thrombolysis. Haemostasis 2001; 31:141-147
141. Moll S, Kenyon P, Bertoli L, et al. Phase II trial of alfimeprase, a novel-acting fibrin degradation agent, for occluded central venous access devices. J Clin Oncol 2006; 24:3056-3060
142. Comer MB, Cackett KS, Gladwell S, et al. Thrombolytic activity of BB-10153, a thrombin-activatable plasminogen. J Thromb Haemost 2005; 3:146-153
143. Curtis LD, Brown A, Comer MB, et al. Pharmacokinetics and pharmacodynamics of BB-10153, a thrombin-activatable plasminogen, in healthy volunteers. J Thromb Haemost 2005; 3:1180-1186
144. Gibson CM, Zorkun C, Molhoek P, et al. Dose escalation trial of the efficacy, safety, and pharmacokinetics of a novel fibrinolytic agent, BB-10153, in patients with ST elevation MI: results of the TIMI 31 trial. J Thromb Thrombolysis 2006; 22:13-21
145. Stewart RJ, Fredenburgh JC, Weitz JI. Characterization of the interactions of plasminogen and tissue and vampire bat plasminogen activators with fibrinogen, fibrin, and the complex of D-dimer noncovalently linked to fragment E. J Biol Chem 1998; 273:18292-18299
146. Meilott MJ, Ramjit DR, Stabilito II, et al. Vampire bat salivary plasminogen activator evokes minimal bleeding relative to tissue-type plasminogen activator as assessed by a rabbit cuticle bleeding time model. Thromb Haemost 1995; 73:478-483
147. Hacke W, Albers G, Al-Rawi Y, et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005; 36:66-73